{"bundle_type":"pith_open_graph_bundle","bundle_version":"1.0","pith_number":"pith:2022:P2LLNMLIRHV2DW4KFCYOQ4ITFE","short_pith_number":"pith:P2LLNMLI","canonical_record":{"source":{"id":"2210.02903","kind":"arxiv","version":1},"metadata":{"license":"http://creativecommons.org/licenses/by-nc-nd/4.0/","primary_cat":"stat.ME","submitted_at":"2022-10-06T13:18:38Z","cross_cats_sorted":["stat.AP"],"title_canon_sha256":"ff60e1e43a98bd165a473c375c37df77ff9cc31bd55b29bd65e68b20414baab0","abstract_canon_sha256":"760fd05cec46611304ec3c2421bed1392c3b68a4c58648365fe685641527d04a"},"schema_version":"1.0"},"canonical_sha256":"7e96b6b16889eba1db8a28b0e87113293ae0ba65047c3cd955a1c161dbb70ff0","source":{"kind":"arxiv","id":"2210.02903","version":1},"source_aliases":[{"alias_kind":"arxiv","alias_value":"2210.02903","created_at":"2026-07-05T05:04:05Z"},{"alias_kind":"arxiv_version","alias_value":"2210.02903v1","created_at":"2026-07-05T05:04:05Z"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.2210.02903","created_at":"2026-07-05T05:04:05Z"},{"alias_kind":"pith_short_12","alias_value":"P2LLNMLIRHV2","created_at":"2026-07-05T05:04:05Z"},{"alias_kind":"pith_short_16","alias_value":"P2LLNMLIRHV2DW4K","created_at":"2026-07-05T05:04:05Z"},{"alias_kind":"pith_short_8","alias_value":"P2LLNMLI","created_at":"2026-07-05T05:04:05Z"}],"events":[{"event_type":"record_created","subject_pith_number":"pith:2022:P2LLNMLIRHV2DW4KFCYOQ4ITFE","target":"record","payload":{"canonical_record":{"source":{"id":"2210.02903","kind":"arxiv","version":1},"metadata":{"license":"http://creativecommons.org/licenses/by-nc-nd/4.0/","primary_cat":"stat.ME","submitted_at":"2022-10-06T13:18:38Z","cross_cats_sorted":["stat.AP"],"title_canon_sha256":"ff60e1e43a98bd165a473c375c37df77ff9cc31bd55b29bd65e68b20414baab0","abstract_canon_sha256":"760fd05cec46611304ec3c2421bed1392c3b68a4c58648365fe685641527d04a"},"schema_version":"1.0"},"canonical_sha256":"7e96b6b16889eba1db8a28b0e87113293ae0ba65047c3cd955a1c161dbb70ff0","receipt":{"kind":"pith_receipt","key_id":"pith-v1-2026-05","algorithm":"ed25519","signed_at":"2026-07-05T05:04:05.169275Z","signature_b64":"py2MtU8z3Tq5mndU6TMswKC8xXTGbGTyPn4GJTN+7J+MKdXjcvGc/pkXQ64Fam04rOmExI/nBQuFdxQOFzUxAQ==","signed_message":"canonical_sha256_bytes","builder_version":"pith-number-builder-2026-05-17-v1","receipt_version":"0.3","canonical_sha256":"7e96b6b16889eba1db8a28b0e87113293ae0ba65047c3cd955a1c161dbb70ff0","last_reissued_at":"2026-07-05T05:04:05.168902Z","signature_status":"signed_v1","first_computed_at":"2026-07-05T05:04:05.168902Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"source_kind":"arxiv","source_id":"2210.02903","source_version":1,"attestation_state":"computed"},"signer":{"signer_id":"pith.science","signer_type":"pith_registry","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"created_at":"2026-07-05T05:04:05Z","supersedes":[],"prev_event":null,"signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"shnwyGZHd9BP5K1ZxTw4TuI+GI75KK+GMq/DEfDuzLg2GA5ueMUgYDpz5LcJbwwJqmugCR7V/tQq28UnB5yJDw==","signed_message":"open_graph_event_sha256_bytes","signed_at":"2026-07-09T00:26:01.188300Z"},"content_sha256":"6ebc704ca961a63ca0c234960f9770b0047db8f70f0d52cb5b66497228bb72d4","schema_version":"1.0","event_id":"sha256:6ebc704ca961a63ca0c234960f9770b0047db8f70f0d52cb5b66497228bb72d4"},{"event_type":"graph_snapshot","subject_pith_number":"pith:2022:P2LLNMLIRHV2DW4KFCYOQ4ITFE","target":"graph","payload":{"graph_snapshot":{"paper":{"title":"Optimal predictive probability designs for randomized biomarker-guided oncology trials","license":"http://creativecommons.org/licenses/by-nc-nd/4.0/","headline":"","cross_cats":["stat.AP"],"primary_cat":"stat.ME","authors_text":"Alexander M. Kaizer, Brian P. Hobbs, Emily C. Zabor, Nathan A. Pennell","submitted_at":"2022-10-06T13:18:38Z","abstract_excerpt":"Efforts to develop biomarker-targeted anti-cancer therapies have progressed rapidly in recent years. Six antibodies acting on programmed death ligand 1 or programmed death 1 pathways were approved in 75 cancer indications between 2015 and 2021. With efforts to expedite regulatory reviews of promising therapies, several targeted cancer therapies have been granted accelerated approval on the basis of single-arm phase II trials. And yet, in the absence of randomization, patient outcomes may not have been studied under standard of care chemotherapies for emerging biomarker subpopulations prior to "},"claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"2210.02903","kind":"arxiv","version":1},"verdict":{"id":null,"model_set":{},"created_at":null,"strongest_claim":"","one_line_summary":"","pipeline_version":null,"weakest_assumption":"","pith_extraction_headline":""},"integrity":{"clean":true,"summary":{"advisory":0,"critical":0,"by_detector":{},"informational":0},"endpoint":"/pith/2210.02903/integrity.json","findings":[],"available":true,"detectors_run":[],"snapshot_sha256":"c28c3603d3b5d939e8dc4c7e95fa8dfce3d595e45f758748cecf8e644a296938"},"references":{"count":0,"sample":[],"resolved_work":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","internal_anchors":0},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"author_claims":{"count":0,"strong_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"builder_version":"pith-number-builder-2026-05-17-v1"},"verdict_id":null},"signer":{"signer_id":"pith.science","signer_type":"pith_registry","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"created_at":"2026-07-05T05:04:05Z","supersedes":[],"prev_event":null,"signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"97+EddBu1DgkjDa6TfcSoJApjW64HqjdGZyGbcHG/ICbfrkvu0F3h9XlqVH65idaLCvJe1zzEAHGsdk8ncMiBQ==","signed_message":"open_graph_event_sha256_bytes","signed_at":"2026-07-09T00:26:01.188689Z"},"content_sha256":"2065daa0b84c7e677c94a3f2474a6e8fa6375496330ed0e44940235219c4297c","schema_version":"1.0","event_id":"sha256:2065daa0b84c7e677c94a3f2474a6e8fa6375496330ed0e44940235219c4297c"}],"timestamp_proofs":[],"mirror_hints":[{"mirror_type":"https","name":"Pith Resolver","base_url":"https://pith.science","bundle_url":"https://pith.science/pith/P2LLNMLIRHV2DW4KFCYOQ4ITFE/bundle.json","state_url":"https://pith.science/pith/P2LLNMLIRHV2DW4KFCYOQ4ITFE/state.json","well_known_bundle_url":"https://pith.science/.well-known/pith/P2LLNMLIRHV2DW4KFCYOQ4ITFE/bundle.json","status":"primary"}],"public_keys":[{"key_id":"pith-v1-2026-05","algorithm":"ed25519","format":"raw","public_key_b64":"stVStoiQhXFxp4s2pdzPNoqVNBMojDU/fJ2db5S3CbM=","public_key_hex":"b2d552b68890857171a78b36a5dccf368a953413288c353f7c9d9d6f94b709b3","fingerprint_sha256_b32_first128bits":"RVFV5Z2OI2J3ZUO7ERDEBCYNKS","fingerprint_sha256_hex":"8d4b5ee74e4693bcd1df2446408b0d54","rotates_at":null,"url":"https://pith.science/pith-signing-key.json","notes":"Pith uses this Ed25519 key to sign canonical record SHA-256 digests. Verify with: ed25519_verify(public_key, message=canonical_sha256_bytes, signature=base64decode(signature_b64))."}],"merge_version":"pith-open-graph-merge-v1","built_at":"2026-07-09T00:26:01Z","links":{"resolver":"https://pith.science/pith/P2LLNMLIRHV2DW4KFCYOQ4ITFE","bundle":"https://pith.science/pith/P2LLNMLIRHV2DW4KFCYOQ4ITFE/bundle.json","state":"https://pith.science/pith/P2LLNMLIRHV2DW4KFCYOQ4ITFE/state.json","well_known_bundle":"https://pith.science/.well-known/pith/P2LLNMLIRHV2DW4KFCYOQ4ITFE/bundle.json"},"state":{"state_type":"pith_open_graph_state","state_version":"1.0","pith_number":"pith:2022:P2LLNMLIRHV2DW4KFCYOQ4ITFE","merge_version":"pith-open-graph-merge-v1","event_count":2,"valid_event_count":2,"invalid_event_count":0,"equivocation_count":0,"current":{"canonical_record":{"metadata":{"abstract_canon_sha256":"760fd05cec46611304ec3c2421bed1392c3b68a4c58648365fe685641527d04a","cross_cats_sorted":["stat.AP"],"license":"http://creativecommons.org/licenses/by-nc-nd/4.0/","primary_cat":"stat.ME","submitted_at":"2022-10-06T13:18:38Z","title_canon_sha256":"ff60e1e43a98bd165a473c375c37df77ff9cc31bd55b29bd65e68b20414baab0"},"schema_version":"1.0","source":{"id":"2210.02903","kind":"arxiv","version":1}},"source_aliases":[{"alias_kind":"arxiv","alias_value":"2210.02903","created_at":"2026-07-05T05:04:05Z"},{"alias_kind":"arxiv_version","alias_value":"2210.02903v1","created_at":"2026-07-05T05:04:05Z"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.2210.02903","created_at":"2026-07-05T05:04:05Z"},{"alias_kind":"pith_short_12","alias_value":"P2LLNMLIRHV2","created_at":"2026-07-05T05:04:05Z"},{"alias_kind":"pith_short_16","alias_value":"P2LLNMLIRHV2DW4K","created_at":"2026-07-05T05:04:05Z"},{"alias_kind":"pith_short_8","alias_value":"P2LLNMLI","created_at":"2026-07-05T05:04:05Z"}],"graph_snapshots":[{"event_id":"sha256:2065daa0b84c7e677c94a3f2474a6e8fa6375496330ed0e44940235219c4297c","target":"graph","created_at":"2026-07-05T05:04:05Z","signer":{"key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signer_id":"pith.science","signer_type":"pith_registry"},"payload":{"graph_snapshot":{"author_claims":{"count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","strong_count":0},"builder_version":"pith-number-builder-2026-05-17-v1","claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"integrity":{"available":true,"clean":true,"detectors_run":[],"endpoint":"/pith/2210.02903/integrity.json","findings":[],"snapshot_sha256":"c28c3603d3b5d939e8dc4c7e95fa8dfce3d595e45f758748cecf8e644a296938","summary":{"advisory":0,"by_detector":{},"critical":0,"informational":0}},"paper":{"abstract_excerpt":"Efforts to develop biomarker-targeted anti-cancer therapies have progressed rapidly in recent years. Six antibodies acting on programmed death ligand 1 or programmed death 1 pathways were approved in 75 cancer indications between 2015 and 2021. With efforts to expedite regulatory reviews of promising therapies, several targeted cancer therapies have been granted accelerated approval on the basis of single-arm phase II trials. And yet, in the absence of randomization, patient outcomes may not have been studied under standard of care chemotherapies for emerging biomarker subpopulations prior to ","authors_text":"Alexander M. Kaizer, Brian P. Hobbs, Emily C. Zabor, Nathan A. Pennell","cross_cats":["stat.AP"],"headline":"","license":"http://creativecommons.org/licenses/by-nc-nd/4.0/","primary_cat":"stat.ME","submitted_at":"2022-10-06T13:18:38Z","title":"Optimal predictive probability designs for randomized biomarker-guided oncology trials"},"references":{"count":0,"internal_anchors":0,"resolved_work":0,"sample":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"2210.02903","kind":"arxiv","version":1},"verdict":{"created_at":null,"id":null,"model_set":{},"one_line_summary":"","pipeline_version":null,"pith_extraction_headline":"","strongest_claim":"","weakest_assumption":""}},"verdict_id":null}}],"author_attestations":[],"timestamp_anchors":[],"storage_attestations":[],"citation_signatures":[],"replication_records":[],"corrections":[],"mirror_hints":[],"record_created":{"event_id":"sha256:6ebc704ca961a63ca0c234960f9770b0047db8f70f0d52cb5b66497228bb72d4","target":"record","created_at":"2026-07-05T05:04:05Z","signer":{"key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signer_id":"pith.science","signer_type":"pith_registry"},"payload":{"attestation_state":"computed","canonical_record":{"metadata":{"abstract_canon_sha256":"760fd05cec46611304ec3c2421bed1392c3b68a4c58648365fe685641527d04a","cross_cats_sorted":["stat.AP"],"license":"http://creativecommons.org/licenses/by-nc-nd/4.0/","primary_cat":"stat.ME","submitted_at":"2022-10-06T13:18:38Z","title_canon_sha256":"ff60e1e43a98bd165a473c375c37df77ff9cc31bd55b29bd65e68b20414baab0"},"schema_version":"1.0","source":{"id":"2210.02903","kind":"arxiv","version":1}},"canonical_sha256":"7e96b6b16889eba1db8a28b0e87113293ae0ba65047c3cd955a1c161dbb70ff0","receipt":{"algorithm":"ed25519","builder_version":"pith-number-builder-2026-05-17-v1","canonical_sha256":"7e96b6b16889eba1db8a28b0e87113293ae0ba65047c3cd955a1c161dbb70ff0","first_computed_at":"2026-07-05T05:04:05.168902Z","key_id":"pith-v1-2026-05","kind":"pith_receipt","last_reissued_at":"2026-07-05T05:04:05.168902Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","receipt_version":"0.3","signature_b64":"py2MtU8z3Tq5mndU6TMswKC8xXTGbGTyPn4GJTN+7J+MKdXjcvGc/pkXQ64Fam04rOmExI/nBQuFdxQOFzUxAQ==","signature_status":"signed_v1","signed_at":"2026-07-05T05:04:05.169275Z","signed_message":"canonical_sha256_bytes"},"source_id":"2210.02903","source_kind":"arxiv","source_version":1}}},"equivocations":[],"invalid_events":[],"applied_event_ids":["sha256:6ebc704ca961a63ca0c234960f9770b0047db8f70f0d52cb5b66497228bb72d4","sha256:2065daa0b84c7e677c94a3f2474a6e8fa6375496330ed0e44940235219c4297c"],"state_sha256":"5c7558e986d0adc21d00457f22e048a3c017e07895edb6e9c14aaff3b71b42cb"},"bundle_signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"AZJkPpqZbqOc0eBmJ3ScGg1OsTGUa+l2b2iWJFx25gtcMPA5lBIcYrKxtq75JxdOKokP+Dy1AmdakyOOgxlHCA==","signed_message":"bundle_sha256_bytes","signed_at":"2026-07-09T00:26:01.190682Z","bundle_sha256":"2366ff61f2d850a43cdcfa6fc41930bd595c03da92fe364fc41b56fbc9d7056f"}}